Advertisement

Topics

RedHill Biopharma Ltd.: RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn's Disease

07:04 EST 9 Nov 2017 | FinanzNachrichten

-- Top-line results are expected to be announced in mid-2018 -- The Phase III study evaluating RHB-104 for Crohn's disease (MAP US study) is a randomized, double-blind, placebo-controlled study tha...

Original Article: RedHill Biopharma Ltd.: RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn's Disease

NEXT ARTICLE

More From BioPortfolio on "RedHill Biopharma Ltd.: RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn's Disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Crohn's Disease (CD)
Crohn’s disease (CD) is a long-term condition that causes inflammation of the lining of the digestive system.  Inflammation can affect any part of the digestive system, from the mouth to the back passage, but most commonly occurs in the last s...